360 related articles for article (PubMed ID: 34076753)
1.
Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
[TBL] [Abstract][Full Text] [Related]
2. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
[TBL] [Abstract][Full Text] [Related]
4.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
5. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
7. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
8. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
[TBL] [Abstract][Full Text] [Related]
9. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
[TBL] [Abstract][Full Text] [Related]
11. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
13.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
14. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
[TBL] [Abstract][Full Text] [Related]
15. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
18. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract][Full Text] [Related]
19. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]